RU2013122843A - Гликоформы антитела против фолатного рецептора альфа - Google Patents

Гликоформы антитела против фолатного рецептора альфа Download PDF

Info

Publication number
RU2013122843A
RU2013122843A RU2013122843/10A RU2013122843A RU2013122843A RU 2013122843 A RU2013122843 A RU 2013122843A RU 2013122843/10 A RU2013122843/10 A RU 2013122843/10A RU 2013122843 A RU2013122843 A RU 2013122843A RU 2013122843 A RU2013122843 A RU 2013122843A
Authority
RU
Russia
Prior art keywords
amino acid
acid sequence
seq
monoclonal antibody
internalization
Prior art date
Application number
RU2013122843/10A
Other languages
English (en)
Russian (ru)
Inventor
Филип М. САСС
Николас НИКОЛЭЙДЕС
Луиджи Грассо
Эрик РУТЬЕ
Вэй ГУ
Джейсон ЯНГ
Цзюнь ЯО
Original Assignee
Морфотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Морфотек, Инк. filed Critical Морфотек, Инк.
Publication of RU2013122843A publication Critical patent/RU2013122843A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2013122843/10A 2010-10-20 2011-10-19 Гликоформы антитела против фолатного рецептора альфа RU2013122843A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39481210P 2010-10-20 2010-10-20
US61/394,812 2010-10-20
PCT/US2011/056966 WO2012054654A2 (en) 2010-10-20 2011-10-19 Anti-folate receptor alpha antibody glycoforms

Publications (1)

Publication Number Publication Date
RU2013122843A true RU2013122843A (ru) 2014-11-27

Family

ID=45975873

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013122843/10A RU2013122843A (ru) 2010-10-20 2011-10-19 Гликоформы антитела против фолатного рецептора альфа

Country Status (12)

Country Link
US (1) US20120164137A1 (https=)
EP (1) EP2629798A4 (https=)
JP (1) JP2014505012A (https=)
KR (1) KR20140032944A (https=)
CN (1) CN103347537A (https=)
AU (2) AU2011317088B2 (https=)
BR (1) BR112013009275A2 (https=)
CA (1) CA2815080A1 (https=)
IL (1) IL225579A0 (https=)
MX (1) MX2013004202A (https=)
RU (1) RU2013122843A (https=)
WO (1) WO2012054654A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607444C (en) * 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
BR112014028306A2 (pt) 2012-05-15 2018-04-17 Morphotek, Inc. métodos para tratamento de câncer gástrico.
US9200073B2 (en) * 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
US9207238B2 (en) 2012-12-07 2015-12-08 Kyowa Hakko Kirin Co., Ltd. Anti-FOLR1 antibody
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
CN113150145B (zh) 2013-08-30 2025-02-14 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
EP2871190A1 (en) * 2013-11-11 2015-05-13 ATLAB Pharma Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
PT3221356T (pt) 2014-11-20 2020-10-29 Hoffmann La Roche Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
EP4141032B1 (en) 2014-11-20 2024-05-29 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
DK3221357T3 (da) 2014-11-20 2020-08-10 Hoffmann La Roche Fælles letkæder og fremgangsmåder til anvendelse
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
CN116440279B (zh) * 2015-09-17 2026-02-24 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
AU2019236091B2 (en) 2018-03-13 2025-06-05 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
KR102275930B1 (ko) * 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
CN118344485B (zh) * 2024-06-18 2024-10-15 南京欧凯生物科技有限公司 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648511A1 (en) * 2003-07-29 2006-04-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
EP3101034A1 (en) * 2004-02-12 2016-12-07 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
AU2005274905B2 (en) * 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
CA2607444C (en) * 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
SG153825A1 (en) * 2005-12-16 2009-07-29 Ibc Pharmaceuticals Inc Multivalent immunoglobulin-based bioactive assemblies
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates

Also Published As

Publication number Publication date
WO2012054654A3 (en) 2012-08-02
IL225579A0 (en) 2013-06-27
AU2011317088A1 (en) 2013-05-02
KR20140032944A (ko) 2014-03-17
EP2629798A4 (en) 2014-05-28
EP2629798A2 (en) 2013-08-28
WO2012054654A2 (en) 2012-04-26
CA2815080A1 (en) 2012-04-26
AU2016202082A1 (en) 2016-04-28
JP2014505012A (ja) 2014-02-27
CN103347537A (zh) 2013-10-09
MX2013004202A (es) 2013-10-17
US20120164137A1 (en) 2012-06-28
AU2011317088B2 (en) 2016-01-21
BR112013009275A2 (pt) 2017-06-20

Similar Documents

Publication Publication Date Title
RU2013122843A (ru) Гликоформы антитела против фолатного рецептора альфа
JP2014505012A5 (https=)
AU2025204722A1 (en) Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
KR102244173B1 (ko) 세포상해 유도 치료제
UA130461C2 (uk) Композиція окиснених варіантів афліберцепту
RU2010125605A (ru) Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
CN105296433A (zh) 一种ctla4抗体、其药物组合物及其用途
PE20140614A1 (es) Anticuerpos anti-cd79b e inmunoconjugados
IL310938A (en) Anti-CCR8 antibodies and their uses
EP3972997A1 (en) Novel anti-cd25 antibodies
CA3055438A1 (en) Multispecific antibody constructs binding to muc1 and cd3
US20220144938A1 (en) Identification and targeting of tumor promoting carcinoma associated fibroblasts for diagnosis and treatment of cancer and other diseases
AU2021365142A9 (en) Novel anti-lilrb2 antibodies and derivative products
WO2020257296A1 (en) Targeting alpha3beta1 integrin for treatment of cancer and other diseases
JP2022033851A (ja) 癌マーカーおよび治療標的としてのグリピカン２
EP3076980A1 (en) A method of treating neoplasia
WO2021056025A2 (en) Anti-epha10 antibodies and methods of use thereof
WO2022106663A1 (en) Anti-cd25 antibodies
RU2013139743A (ru) Гуманизированное моноклональное антитело, специфичное к синдекану-1
CN104651314B (zh) 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子
CN107460221A (zh) 一种降低抗pd‑l1抗体中蛋白聚合物的细胞培养方法
JP7854991B2 (ja) 新規の抗ｌｉｌｒｂ２抗体および誘導体生成物
AU2021380966A1 (en) Anti-cd25 antibodies
RU2535982C1 (ru) Штамм культивируемых гибридных клеток животного mus musculus l. cchfv vd-1-продуцент моноклонального антитела 4g4/b6 к вирусу крым-конго геморрагической лихорадки
EP4274617A1 (en) An agr2xcd3 bispecific engager for the treatment of cancer

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160617